The results show that salsalate is effective in improving glycemic control in newly diagnosed naive patients with type 2 diabetes.…
Read More »Yearly Archives: 2011
Novo Files for Degludec and DegludecPlus Approval in Europe
Novo Nordisk has filed for regulatory approval of the ultra-long-acting insulins Degludec and DegludecPlus in Europe. According to their press release Novo will also be submitting both drugs to the FDA within two weeks. Both drugs will be available with a pen delivery system.
Read More »Special Edition: Early Insulin Initiation
More and more of our patients are developing diabetes, many of them at a much earlier age, so treatment has to be more focused and intense: the sooner this starts the better. This Special Edition brings you the background and basis for starting insulin therapy earlier. Two leading endocrinologists, Dr. …
Read More »Viewpoints on Early Insulin Initiation
Diabetes In Control staff contacted several physicians all across the US to find out what they had to say about early insulin initiation. What they said may surprise you….
Read More »The Role of Insulin Pens in Addressing Barriers to Insulin Therapy
The advantages of insulin pens may reduce resistance to initiating and adhering to insulin therapy. Many patients resist insulin initiation due to concerns about complexity or a general resistance to injections; many patients’ concerns about insulin initiation may stem from perceptions about the pain and inconvenience of using vials and …
Read More »Dr. Stanley Schwartz on Early Insulin Use
Stanley Schwartz, MD, FACP, FACE, shares his views on early insulin initiation. Insulin is the most effective agent available for lowering glycemia. If given in appropriate doses, insulin may decrease any elevated HbA1c to, or close to, the therapeutic goal. However, insulin therapy is associated with weight gain of 2 …
Read More »Dr. Aaron I. Vinik on Early Insulin Use in the Progression of Diabetes
One of the leading diabetes researchers in the world, Dr. Aaron I. Vinik, Director of Research and Neuroendocrine Unit, EVMS Strelitz Diabetes Research Center, shares his views on early insulin initiation. The natural history of type 2 Diabetes (T2DM) is a progressive worsening of glycemic control as a consequence of …
Read More »Editor’s Note: Our One-Year Anniversary
This week marks one year since we started delivering our Diabetes Clinical Mastery Series newsletter, and Steve, Andrew, Heather and I appreciate the great support you have given us. According to your emails, the Homerun Slides have provided great materials for your talks, and there have been enough comments about …
Read More »Early Use of Insulin to Improve Beta Cell Preservation
By David Joffe, BSPharm, CDE; Steve Freed, BSPharm CPT; Brandon Flohr, PharmD, and Vanessa Cepero, PharmD, CVS Pharmacy Type 2 diabetes is a heterogeneous disorder, characterized by glucotoxicity, beta cell dysfunction and decreased insulin sensitivity. Presence of amyloid deposits in the islets and decreased beta cell mass are the pathological hallmark …
Read More »Managing Clinical Problems in Diabetes, Case Study #23: Type 1 and Pre-Teens
Edited by Trisha Dunning AM, RN, MEd, PhD, CDE, FRCNA and Glenn Ward MBBS, BSc, DPhil (Oxon), FRACP, FRCPath Jade, an 11-year-old girl, was admitted via the emergency department with hyperglycemia, ketonuria and a weight loss of 6 kg over the past 4 weeks. The only history of diabetes in …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.